Table 3: Analysis of Factors Affecting Survival, Relapse Rate and Nonrelapse Mortality (NRM)

Survival RateAfter SCT P Value Relapse RateAfter SCT P Value NRM P Value
All 30 PATIENTS 17/30 (57%) / 7/30 (23%) / 6/30 (20%) /
STATUS of AML at SCT
  • Complete Remission
  • Active Disease (Rel/Res)
 15/18
2/18 		0,0004 1/18
6/12 		0,008 3/18
3/12 		0.3
DONOR
  • Sibling
  • Unrelated
 10/18
7/12 		0,6 3/18
4/12 		0,3 4/18
2/12 		0.5
STEM CELL SOURCE
  • Bone Marrow
  • Pheripheral Blood
 6/11
11/10 		0,7 2/11
5/19 		0,5 3/11
3/19 		0.3
PREPARATIVE REGIMEN
  • Tyothepa-EDX ± ATG
  • Fluda based-RIC
  • Bu-EDX ± ATG
 9/14
7/12
1/4 		0,2 2/14
4/12
1/4 		0,8 3/14
1/12
2/4 		0.15
AGE
  • < 65
  • > 65
 10/17
7/13 		0,7 4/17
3/13 		0,7 3/17
3/13 		0.3
HCT-CI
  • < 2
  • > 3
 10/12
7/18 		0,02 2/12
5/18 		0,4 0/12
6/18 		0.03